This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
By Allessandra DiCorato October 11, 2023 In 2011, Robert Manguso was working in a cellbiology lab when his mother was diagnosed with Merkel cell carcinoma, a rare and aggressive skin cancer. By then, a few cancer immunotherapies had entered clinical trials and only a handful had been approved by the FDA.
NK cells are among the front line of protection from infected and abnormal cells as part of the ‘innate immuneresponse’. They recognise ‘cell stress molecules’ on the surface of infected, old, injured and cancerous cells without the need for complex pre-stimulation signals of the adaptive immune system (eg, T cells).
By harvesting, expanding, and injecting CD34+ cells directly to the heart muscle, this natural repair mechanism is enhanced. Early-phase clinical trials have shown the safety and efficacy of using stem cells for cardiac repair, encouraging further research and development. Allogeneic cell therapies must avoid immune rejection.
Both will help NexImmune advance current early-stage clinical trials and will guide Company’s translational efforts to develop new immunotherapy products.
Both Jerry and Jeff have proven and successful track records in the design and execution of early and late-stage clinical trials that have evaluated novel immune therapies.
In one experiment, the microneedle patches were used to deliver a SARS-CoV-2 vaccine into mice, producing immuneresponses similar to a traditional injection. Printed vaccines caused mice to have a faster immuneresponse. Nature CellBiology. It’s gonna be used for phase 3 trials of a C.
In one experiment, the microneedle patches were used to deliver a SARS-CoV-2 vaccine into mice, producing immuneresponses similar to a traditional injection. Printed vaccines caused mice to have a faster immuneresponse. Nature CellBiology. It’s gonna be used for phase 3 trials of a C.
Read Neoadjuvant enoblituzumab in localized prostate cancer: a single-arm, phase 2 trial. Read Hematopoietic stem-cell gene therapy is associated with restored white matter microvascular function in cerebral adrenoleukodystrophy. Nature CellBiology. McGrady N.R. Molecular Therapy. Shenderov E. Nature Medicine.
Learnings regarding immune geography and cell:cell contact are increasingly important as we consider how best to advance cell therapies for diverse hematologic malignancies and solid tumors ( www.aletabio.com ). Fc-hacking immuneresponses. Therefore, TILs are not always terminally exhausted.
This looks like an early step toward a much different future for biology: One in which natural language is used to design experiments, program robots, and automate experiments in high-throughput. Skin microbes can trigger strong immuneresponses. epidermidis , can actually trigger tumor-specific T cells. Nature Protocols.
We organize all of the trending information in your field so you don't have to. Join 15,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content